Impact of EGFR genetic variants on glioma risk and patient outcome

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 12, 2011, Pages 2610-2617

  Costa, Bruno Marques ^a,b   Viana Pereira, Marta ^a,b   Fernandes, Ricardo ^a,b   Costa, Sandra ^a,b   Linhares, Paulo ^c   Vaz, Rui ^c   Pinheiro, Céline ^a,b   Lima, Jorge ^d   Soares, Paula ^d,e   Silva, Ana ^f   Pardal, Fernando ^f   Amorim, Júlia ^f   Nabiço, Rui ^f   Almeida, Rui ^f   Alegria, Carlos ^f   Pires, Manuel Melo ^g   Pinheiro, Célia ^g   Carvalho, Ernesto ^g   Oliveira, Pedro ^d   Lopes, José M ^d,e   Reis, Rui M ^a,b,h   more..

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e University of Porto   (Portugal)

^f HOSPITAL DE BRAGA   (Portugal)

^g Hospital S Antonio   (Portugal)

^h BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; GLIOMA; HUMANS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS;

EID: 83055168559     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0340     Document Type: Article

References (45)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon, France: IARC; 2007.
2. CBTRUS. Statistical report: primary brain tumors in the United States, 1998-2002. Hinsdale (IL): CBTRUS; 2005.
3. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253-65. (Pubitemid 46622028)
4. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006;24:1246-52. (Pubitemid 46622027)
5. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol 2010;67:279-83.
6. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006;24:1273-80. (Pubitemid 46622030)
7. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005;109:93-108. (Pubitemid 40287792)
8. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'Yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-68.
9. Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, et al. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010;70:453-62.
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
11. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. (Pubitemid 43357943)
12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
13. Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res 2008;28:913-20. (Pubitemid 351578937)
14. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-26. (Pubitemid 37328928)
15. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 2007;4:e125.
16. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63:1589-95. (Pubitemid 36373648)
17. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 2007;12:201-10.
18. Zhang YM, Cao C, Liang K. Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol 2010;34:150-6.
19. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007;13:2621-6. (Pubitemid 46788028)
20. Liu W, He L, Ramirez J, Krishnaswamy S, Kanteti R, Wang YC, et al. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 2011;7:2423-7
21. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53. (Pubitemid 40070794)
22. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 2006;67:872-4. (Pubitemid 44403593)
23. Chi DD, Hing AV, Helms C, Steinbrueck T, Mishra SK, Donis-Keller H. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro alpha 2 (I) collagen (COL1A2). Hum Mol Genet 1992;1:135.
24. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-80.
25. Butler JM, Buel E, Crivellente F, McCord BR. Forensic DNA typing by capillary electrophoresis using the ABI Prism 310 and 3100 genetic analyzers for STR analysis. Electrophoresis 2004;25:1397-412. (Pubitemid 38885802)
26. Kang D, Gridley G, Huang WY, Engel LS, Winn DM, Brown LM, et al. Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics 2005;15:343-7. (Pubitemid 40676556)
27. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64. (Pubitemid 35346467)
28. Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43. (Pubitemid 39665528)
29. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3. (Pubitemid 27157309)
30. Etienne-Grimaldi MC, Pereira S, Magne N, Formento JL, Francoual M, Fontana X, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2005;16:934-41. (Pubitemid 40903920)
31. Zhang W, Weissfeld JL, Romkes M, Land SR, Grandis JR, Siegfried JM. Association of the EGFRintron 1CArepeat length with lung cancer risk. Mol Carcinog 2007;46:372-80. (Pubitemid 46744457)
32. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005;11:600-5. (Pubitemid 40116885)
33. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 2004;64:7-12. (Pubitemid 38114073)
34. Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42. (Pubitemid 38443646)
35. Costa BM, Caeiro C, Guimaraes I, Martinho O, Jaraquemada T, Augusto I, et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 2010;23:1655-62.
36. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005;92:241-5. (Pubitemid 40343136)
37. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
38. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990;87:4207-11.
39. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992;89:2965-9.
40. Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005;3:38.
41. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 2007;13:6788-95. (Pubitemid 350206817)
42. Schwartzbaum JA, Xiao Y, Liu Y, Tsavachidis S, Berger MS, Bondy ML, et al. Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis 2010;31:1770-7.
43. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol 2010;49:767-75.
44. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, et al. Allelic length of aCAdinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol 2004;203:545-50. (Pubitemid 38529034)
45. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-7. (Pubitemid 30129514)